NASDAQ:TBPH Theravance Biopharma (TBPH) Stock Price, News & Analysis $17.03 0.00 (0.00%) As of 11/6/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Theravance Biopharma Stock (NASDAQ:TBPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Theravance Biopharma alerts:Sign Up Key Stats Today's Range$17.03▼$17.0350-Day Range$17.01▼$17.0652-Week Range$13.08▼$21.03VolumeN/AAverage Volume680,323 shsMarket Capitalization$884.18 millionP/E Ratio16.86Dividend YieldN/APrice Target$19.00Consensus RatingHold Company Overview Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines. Its marketed product, YUPELRI (revefenacin), is a once-daily nebulized treatment for the maintenance of chronic obstructive pulmonary disease (COPD) in adults. In the United States, the product is commercialized through a collaboration with Viatris. The company was established as an independent business following its separation from Theravance, Inc. in 2014. Its research and development work has included therapies for respiratory and other serious conditions. Theravance Biopharma is led by Chief Executive Officer Rick E. Winningham.AI Generated. May Contain Errors. Read More Theravance Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreTBPH MarketRank™: 1.54825026511 of 5 starsTheravance Biopharma scored higher than 31% of companies evaluated by MarketBeat, and ranked 764th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingHold Consensus RatingTheravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and no sell ratings.Upside PotentialTheravance Biopharma has a consensus price target of $19.00, representing about 11.6% upside from its current price of $17.03.Amount of Analyst CoverageTheravance Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Theravance Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-48.08% Earnings GrowthEarnings for Theravance Biopharma are expected to decrease by -48.08% in the coming year, from $1.56 to $0.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theravance Biopharma is 16.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.15.Price to Earnings Ratio vs. SectorThe P/E ratio of Theravance Biopharma is 16.86, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.34.Price to Book Value per Share RatioTheravance Biopharma has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for TBPH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTheravance Biopharma does not currently pay a dividend.Dividend GrowthTheravance Biopharma does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment0.36 News SentimentTheravance Biopharma has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Theravance Biopharma this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $226,737.00 in company stock.Percentage Held by Insiders7.65% of the stock of Theravance Biopharma is held by insiders.Percentage Held by Institutions99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Theravance Biopharma's insider trading history. Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TBPH Stock News HeadlinesTheravance Biopharma, Inc. (NASDAQ:TBPH) Stock Has Average Target Price of $19.00November 16 at 2:01 AM | americanbankingnews.comTheravance Biopharma (TBPH) Set to Release Earnings on TuesdayNovember 9, 2026 | americanbankingnews.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 16 at 1:00 AM | Behind the Markets (Ad)Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell Small Cap Completeness IndexSeptember 24, 2026 | marketscreener.comMZymeworks Inc. (NasdaqGS:ZYME) hat Theravance Biopharma, Inc. (NasdaqGM:TBPH) übernommen.September 24, 2026 | de.marketscreener.comDTheravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P TMI IndexSeptember 23, 2026 | marketscreener.comMTheravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Global BMI IndexSeptember 22, 2026 | marketscreener.comMZymeworks' Theravance Deal Is A Breath Of Fresh Cash FlowSeptember 18, 2026 | seekingalpha.comSee More Headlines TBPH Stock Analysis - Frequently Asked Questions How have TBPH shares performed this year? Theravance Biopharma's stock was trading at $18.71 at the beginning of the year. Since then, TBPH stock has decreased by 9.0% and is now trading at $17.03. How were Theravance Biopharma's earnings last quarter? Theravance Biopharma, Inc. (NASDAQ:TBPH) announced its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by $0.18. The biopharmaceutical company earned $20.73 million during the quarter, compared to analysts' expectations of $22.49 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 0.77% and a net margin of 51.58%. What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Salesforce (CRM), NIO (NIO), ACADIA Pharmaceuticals (ACAD), JD.com (JD) and Micron Technology (MU). Company Calendar Last Earnings8/10/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TBPH's financial health is in the Red zone, according to TradeSmith. TBPH has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CIK1583107 Webwww.theravance.com Phone(650) 808-6000FaxN/AEmployees110Year Founded1996Price Target and Rating Average Price Target for Theravance Biopharma$19.00 High Price Target$27.00 Low Price Target$15.00 Potential Upside/Downside+11.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$1.01 Trailing P/E Ratio16.86 Forward P/E Ratio21.02 P/E GrowthN/ANet Income$105.89 million Net Margins51.58% Pretax Margin56.48% Return on Equity-0.77% Return on Assets-0.46% Debt Debt-to-Equity RatioN/A Current Ratio13.54 Quick Ratio13.54 Sales & Book Value Annual Sales$104.31 million Price / Sales8.48 Cash FlowN/A Price / Cash FlowN/A Book Value$5.86 per share Price / Book2.91Miscellaneous Outstanding Shares51,919,000Free Float47,947,000Market Cap$884.18 million OptionableOptionable Beta0.25 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:TBPH) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman and Jensen Huang could one day be worth more than Ap...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.